Changes in neurotransmitter-related functional connectivity along the Alzheimer's disease continuum. [PDF]
Manca R+4 more
europepmc +1 more source
Acetylcholine muscarinic M2 receptor maintains human Schwann-like adipose-derived phenotype in the absence of differentiating medium. [PDF]
Piovesana R, Faroni A, Tata AM, Reid AJ.
europepmc +1 more source
Control of cortical slow oscillations and epileptiform discharges with photoswitchable type 1 muscarinic ligands. [PDF]
Sanchez-Sanchez JM+11 more
europepmc +1 more source
Inhibitory effect of Zhujing Pill on myopia progression: Mechanistic insights based on metabonomics and network pharmacology. [PDF]
Du Y+12 more
europepmc +1 more source
AiGPro: a multi-tasks model for profiling of GPCRs for agonist and antagonist. [PDF]
Brahma R, Moon S, Shin JM, Cho KH.
europepmc +1 more source
Alzheimer's disease treatment landscape: current therapies and emerging mechanism-targeted approaches. [PDF]
Yang E, Abd-Elrahman KS.
europepmc +1 more source
Discovery of Pre-Clinical Candidate <b>VU6008055</b>/<b>AF98943</b>: A Highly Selective, Orally Bioavailable, and Structurally Distinct Tricyclic M<sub>4</sub> Muscarinic Acetylcholine Receptor Positive Allosteric Modulator (PAM) with Robust In Vivo Efficacy. [PDF]
Engers JL+26 more
europepmc +1 more source
Long-term muscarinic inhibition increases intrinsic excitability through the upregulation of A-type potassium currents in cortical neurons. [PDF]
Riquelme D+4 more
europepmc +1 more source